Inhibitex, Inc.
Records under this name other than the patents Inhibitex, Inc. holds now: patents now held by others, patents whose terms have ended, and its applications, pending or abandoned. None of them is counted in the 1 patents it holds.
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 8,475,798 | Monoclonal Antibodies Recognizing a Coagulase-Negative Staphylococcal Protein Formerly held In force · High confidence | In force | High confidence | |
| US 9,351,989 | Substituted purine nucleosides, phosphoroamidate and phosphorodiamidate derivatives for treatment of viral infections Formerly held In force · From the USPTO record | In force | From the USPTO record | |
| US 7,615,616 | Bioinformatic Method for Identifying Surface-Anchored Proteins from Gram-Positive Bacteria and Proteins Obtained Thereby Term ended Term ended Apr 27, 2025 · High confidence | Term ended | Term ended Apr 27, 2025 | High confidence |
| US 7,850,974 | Bioinformatic method for identifying surface-anchored proteins from gram-positive bacteria and proteins obtained thereby Term ended Term ended Sep 15, 2023 · From the USPTO record | Term ended | Term ended Sep 15, 2023 | From the USPTO record |
| US 7,115,264 | Monoclonal antibodies to the fibronectin binding protein and method of use in treating or preventing infections Term ended Term ended Nov 5, 2022 · From the USPTO record | Term ended | Term ended Nov 5, 2022 | From the USPTO record |
| US 7,364,738 | Monoclonal antibodies to the CLFA protein and method of use in treating infections Term ended Term ended Oct 31, 2022 · From the USPTO record | Term ended | Term ended Oct 31, 2022 | From the USPTO record |
| US 6,841,154 | Cross-reactive monoclonal and polyclonal antibodies which recognize surface proteins from coagulase-negative staphylococci and Staphylococcus aureus Formerly held Term ended Term ended Jun 17, 2022 · From the USPTO record | Term ended | Term ended Jun 17, 2022 | From the USPTO record |
| US 7,968,100 | Surface proteins from coagulase-negative staphylococci and Staphylococcus aureus that generate cross-reactive monoclonal and polyclonal antibodies Term ended Term ended Jun 17, 2022 · From the USPTO record | Term ended | Term ended Jun 17, 2022 | From the USPTO record |
| US 6,979,446 | Monoclonal antibodies to the ClfA protein and method of use in treating or preventing infections Term ended Term ended Jan 28, 2022 · From the USPTO record | Term ended | Term ended Jan 28, 2022 | From the USPTO record |
| US 7,666,438 | Multicomponent Vaccines Formerly held Term ended Term ended Sep 12, 2021 · Medium confidence | Term ended | Term ended Sep 12, 2021 | Medium confidence |